ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstracts tagged "Behcet’s syndrome"

  • Abstract Number: 1694 • 2019 ACR/ARP Annual Meeting

    Pharmacogenetics and Pharmacodynamics of Response to Apremilast in a Phase 3 Clinical Study in Subjects with Active Behçet’s Disease

    Joseph Maranville1, Irina Medvedeva 1, Robert Yang 1, Mindy Chen 2, Lorraine (Ruoying) Fang 2, Sandra Collazo 3, Shannon McCue 3, Marla Hochfeld 3 and Peter Schafer 3, 1Celgene Corporation, Cambridge, MA, 2Celgene Corporation, Berkeley Heights, NJ, 3Celgene Corporation, Summit, NJ

    Background/Purpose: This was an exploratory analysis of genetic polymorphisms, plasma biomarkers, and blood leukocytes with clinical response in the phase 3 clinical study CC-10004-BCT-002 (NCT02307513).Methods:…
  • Abstract Number: 1695 • 2019 ACR/ARP Annual Meeting

    Apremilast in Combination vs Monotherapy for Refractory Oral And/or Genital Ulcers in Behçet’s Disease: National Multicenter Study of 51 Cases

    Belén Atienza-Mateo1, Mónica Calderón-Goercke 2, DIANA PRIETO- PENA 3, Iñigo Gonzalez-Mazon 3, Lara Sanchez-Bilbao 1, Jose Luis Martín-Varillas 1, Javier Loricera 4, Vanesa Calvo Río 1, Jenaro Graña 5, Gerard Espinosa 6, Clara Moriano 7, Trinidad Pérez-Sandoval 7, Manuel Martín-Martínez 7, Elvira Díez 7, María Dolores García-Armario 8, Esperanza Martínez 8, Ivan Castellvi 9, Patricia Moya Alvarado 10, Francisca Sivera 11, Jaime Calvo-Alen 12, Isabel de la Morena 13, Francisco Ortiz-Sanjuán 14, José Andrés Román-Ivorra 14, Ana Pérez-Gómez 15, Sergi Heredia 16, Alejandro Olivé-Marqués 16, Águeda Prior-Español 17, Carolina Díez 18, Juan José Alegre-Sancho 19, Amparo Ybáñez 19, Ángels Martínez-Ferrer 19, Javier Narváez 20, Ignasi Figeras 21, Ana Turrión 22, Susana Romero-Yuste 23, Pilar Trénor 24, Soledad Ojeda 25, Miguel Á. González-Gay 26 and Ricardo Blanco 26, 1Rheumatology, Hospital Universitario Marques de Valdecilla, Santander, Spain, 2Hospital Marqués de Valdecilla, Santander, Cantabria, Spain, 3Rheumatology, Hospital Universitario Marques de Valdecilla, Santander, Cantabria, Spain, 4Rheumatology Department. Hospital Marqués de Valdecilla, Santander, Cantabria, Spain, 5Centro Médico Quirón A Coruña, A Coruña, Galicia, Spain, 6Department of Autoimmune Diseases, Hospital Clínic, Barcelona, Barcelona, Catalonia, Spain, 7Complejo Asistencial Universitario de León, León, Castilla y Leon, Spain, 8Hospital Lluís Alcanyís, Xàtiva, Comunidad Valenciana, Spain, 9Hospital de la Santa Creu i Sant Pau, Barcelona, Spain, 10Hospital de la Santa Creu i Sant Pau, Barcelona, Catalonia, Spain, 11Hospital General Universitario de Elda, Elda, Spain, 12Hospital Universitario Araba, Vitoria-Gasteiz, Spain, 13Hospital General Universitario de Valencia, Valencia, Comunidad Valenciana, Spain, 14Hospital Universitario y Politécnico La Fe, Valencia, Comunidad Valenciana, Spain, 15Hospital Universitario Príncipe de Asturias, Alcalá de Henares, Madrid, Spain, 16Hospital Universitari Germans Trias i Pujol, Badalona, Catalonia, Spain, 17Hospital Universitari Germans Trias i Pujol, Badalona, Spain, 18Hospital de El Bierzo, León, Castilla y Leon, Spain, 19Hospital Universitario Doctor Peset, Valencia, Comunidad Valenciana, Spain, 20Rheumatology Department, Hospital Universitari de Bellvitge, Barcelona, Catalonia, Spain, 21Hospital Bellvitge, Barcelona, Catalonia, Spain, 22Hospital Clínico Universitario de Salamanca, Salamanca, Spain, 23Complejo Hospitalario Universitario Pontevedra, Pontevedra, Galicia, Spain, 24Hospital Clínico Universitario de Valencia, Valencia, Comunidad Valenciana, Spain, 25Hospital Doctor Negrín, Las Palmas de Gran Canaria, Canarias, Spain, 26Hospital Universitario Marqués de Valdecilla, Santander, Cantabria, Spain

    Background/Purpose: Oral and/or genital aphthous ulcers are the most common symptoms of Behçet´s disease (BD), and are often refractory to conventional treatment. The inhibitor of…
  • Abstract Number: 1696 • 2019 ACR/ARP Annual Meeting

    Is the Risk of Tuberculosis Increased in Behçet’s Disease Compared to Other Rheumatological Disorders After Anti-TNF-α Treatment?

    Ummugulsum Gazel 1, Derya Kocakaya 2, Irem Topcu 3, Hakan Karatas 4, Murat Karabacak 5, Pamir Atagunduz 6, Nevsun Inanc 7, Fatma Alibaz-Oner 5 and Haner Direskeneli8, 1Marmara University, Faculty of Medicine, Department of Rheumatology, Istanbul, Turkey, Istanbul, Turkey, 2Marmara University Faculty of Medicine Department of Chest Diseases, Istanbul, Turkey, Istanbul, Istanbul, Turkey, 3Marmara University, School of Medicine, Istanbul,Turkey, ıstanvul, Turkey, 4Marmara University ,School of Medicine, Istanbul,Turkey, Istanbul, Turkey, 5Marmara University Faculty of Medicine,Department of Rheumatology,Istanbul,Turkey, Istanbul, Turkey, 6Marmara University Faculty of Medicine,Department of Rheumatology, Istanbul, Turkey, Istanbul, Turkey, 7Marmara University, Faculty of Medicine, Division of Rheumatology, Istanbul, Turkey, ISTANBUL, Turkey, 8Marmara University, School of Medicine, Division of Rheumatology, Istanbul, Turkey

    Background/Purpose: Tumor necrosis factor (TNF)-α inhibitors are extensively utilized in the treatment of inflammatory rheumatic diseases. These agents increase the risk of tuberculosis (TB), especially…
  • Abstract Number: 1795 • 2018 ACR/ARHP Annual Meeting

    New Major Organ Involvement Is Lower in Young Male Behçet’s Patients Compared to Retrospective Series: Five-Year Results of a Prospective Cohort

    Fatma Alibaz-Oner1, Belgin Aldag2, Emrah Karatay3, Gonca Mumcu4, Tulin Ergun5 and Haner Direskeneli6, 1Rheumatology, Marmara University School of Medicine, Istanbul, Turkey, 2Marmara University, School of Medicine, Rheumatology, Istanbul, Turkey, 3Radiology, Marmara University, School of Medicine, Istanbul, Turkey, 4Department of Health Management, Marmara University, Faculty of Health Sciences, Istanbul, Turkey, 5Marmara University, School of Medicine, Dermatology, Istanbul, Turkey, 6Rheumatology, Marmara University, School of Medicine, Istanbul, Turkey

    Background/Purpose: Major organ involvement such as vascular or ocular disease, especially in young males, is one of the main causes of mortality and morbidity in…
  • Abstract Number: 1814 • 2018 ACR/ARHP Annual Meeting

    Interferon-Alpha for the Management of Lower Extremity Deep Vein Thrombosis in Behcet’s Syndrome: A Case Series

    Yesim Ozguler1, Gulen Hatemi2, Firat Cetinkaya3, Koray Tascilar4, Serdal Ugurlu1, Emire Seyahi1, Hasan Yazici1 and Melike Melikoglu1, 1Istanbul University, Cerrahpasa Medical Faculty, Department of Internal Medicine, Division of Rheumatology, Istanbul, Turkey, 2Istanbul University Cerrahpasa Medical School, Istanbul, Turkey, 3Istanbul University, Cerrahpasa Medical Faculty, Department of Radiology, Istanbul, Turkey, 4Numune Research and Teaching Hospital, Ankara, Turkey

    Background/Purpose: Lower extremity deep vein thrombosis (LEDVT) is a disabling complication of Behcet’s syndrome (BS). Relapses are frequent and cause permanent disability due to post-thrombotic…
  • Abstract Number: 1796 • 2018 ACR/ARHP Annual Meeting

    Retrospective Analysis of Initial Presentation Findings of Behcet’s Syndrome throughout 4 Decades

    Elif Dincses1, Yesim Ozguler2, Didar Ucar3, Yilmaz Ozyazgan4, Serdal Ugurlu2, Gulen Hatemi2, Melike Melikoglu2, Sebahattin Yurdakul2, Hasan Yazici5 and Emire Seyahi2, 1Istanbul University, Cerrahpasa Medical Faculty, Department of Internal Medicine, Division of Rheumatology, İstanbul, Turkey, 2Istanbul University, Cerrahpasa Medical Faculty, Department of Internal Medicine, Division of Rheumatology, Istanbul, Turkey, 3Ophthalmology, Istanbul University, Cerrahpasa Medical Faculty, Department of Ophthalmology, Istanbul, Turkey, 4Istanbul University, Cerrahpasa Medical Faculty, Department of Ophthalmology, Istanbul, Turkey, 5Istanbul Academic Hospital, Istanbul, Turkey

    Background/Purpose: There is some evidence that incident Behcet’s syndrome (BS) might be becoming less severe (1, 2). We compared clinical findings at presentation of BS…
  • Abstract Number: 1815 • 2018 ACR/ARHP Annual Meeting

    Aneurysmal Lesions in Behcet’s Disease: A Report of 69 Cases from a Single Center

    Jiaxin Zhou1, Jing Shi2, Xiuhua Wu2, JinJing Liu2 and Wenjie Zheng2, 1Department of Rheumatology, Peking Union Medical College Hospital, Beijing, China, 2Rheumatology, Peking Union Medical College Hospital, Beijing, China

    Background/Purpose: To analyze the clinical features of patients with Behcet’s disease(BD) complicated with aneurysmal lesions. Methods: We retrospectively reviewed the clinical data of patients with…
  • Abstract Number: 1797 • 2018 ACR/ARHP Annual Meeting

    An Update on Pulmonary Artery Involvement in Behcet’s Syndrome: More Pulmonary Artery Thrombotic Disease and a Better Outcome

    Yesim Ozguler1, Elif Dincses2, Selim Bakan3, Gulen Hatemi1, Melike Melikoglu1, Sebahattin Yurdakul1, Hasan Yazici1 and Emire Seyahi1, 1Istanbul University, Cerrahpasa Medical Faculty, Department of Internal Medicine, Division of Rheumatology, Istanbul, Turkey, 2Istanbul University, Cerrahpasa Medical Faculty, Department of Internal Medicine, Division of Rheumatology, İstanbul, Turkey, 3Istanbul University, Cerrahpasa Medical Faculty, Department of Radiology, ISTANBUL, Turkey

    Background/Purpose: Pulmonary artery involvement (PAI) is the most common form of arterial involvement in Behçet’s syndrome (BS). A previous survey (1) by our group had…
  • Abstract Number: 1975 • 2018 ACR/ARHP Annual Meeting

    Behcet’s Disease Lies in the “B” Holder. New Associations in Disease Susceptibility and Manifestations

    Mohanad Elfishawi1,2, Sally Elfishawi3, Ghada Mossallam3, Paul Norman4, Jill Hollenbach5, Maneesh Misra5, Gonzalo Montero Martin6, Helma de Bruin7, Leos Van de Pasch7, Erik Rozemuller7, Marcelo Fernandiz-Vina6, Adriana Abrudescu8 and Khaled Zaky9, 1Internal Medicine, Icahn School of Medicine at Mount Sinai, Queens Hospital Center, New York, NY, 2Rheumatology, Kasr Alainy Hospital, Cairo University, Cairo, Egypt, 3Clinical pathology and Immunology laboatory, National Cancer Institute, Cairo University, Cairo, Egypt, 4Division of Personalized Medicine and Department of Immunology, University of Colorado School of Medicine, Denver, CO, 5Department of Neurology, University of California San Francisco, San Francisco, CA, 6Department of Pathology, Stanford University,School of medicine, Palo Alto, CA, 7GenDx, Utrecht, Netherlands, 8Internal Medicine and Rheumatology, Icahn School of Medicine at Mount Sinai, Queens Hospital center, NYC, NY, 9Rheumatology and Rehabilitation, Faculty of medicine, Al-Azhar University, Cairo, Egypt

    Background/Purpose: Behçet’s disease is a multisystem disease affecting young adults with variable vessel vasculitis as its underlying pathology. Previous studies in Behçet’s disease linked it…
  • Abstract Number: 1798 • 2018 ACR/ARHP Annual Meeting

    Leg Ulcers in Behçet’s Syndrome: An Observational Survey in 24 Patients

    Yesim Ozguler1, Zekayi Kutlubay2, Atilla Süleyman Dikici3, Melike Melikoglu1, Cem Mat2, Hasan Yazici1 and Emire Seyahi1, 1Istanbul University, Cerrahpasa Medical Faculty, Department of Internal Medicine, Division of Rheumatology, Istanbul, Turkey, 2Istanbul University, Cerrahpasa Medical Faculty, Department of Dermatology, Istanbul, Turkey, 3Radiolgy, Istanbul University, Cerrahpasa Medical Faculty, Department of Radiology, Istanbul, Turkey

     Background/Purpose: Formal experience with leg ulcers in Behcet’s syndrome (BS) is limited. It is a relatively rare complication that can be seen during the course…
  • Abstract Number: 2166 • 2018 ACR/ARHP Annual Meeting

    Treatment of Venous Thrombotic Events in Behçet Disease: A Systematic Literature Review

    Iustina Janta1, Roberto González2, Tania Gudu3 and Indalecio Monteagudo1, 1Rheumatology, Hospital General Universitario Gregorio Marañón, Madrid, Spain, 2Rheumatology, Hospital general Universitario Gregorio Marañón, Madrid, Spain, 3University of Medicine Carol Davila Bucuresti, Romania, Bucuresti, Romania

    Background/Purpose: Venous thrombosis (VT) is a serious and potentially life-threatening manifestation of Behçet disease (BD). However, there is little evidence of the management of the…
  • Abstract Number: 1799 • 2018 ACR/ARHP Annual Meeting

    Increased Vein Wall Thickness in Behçet’s Syndrome

    Migena Gjoni1, Serkan Akbaş2, Emine Şebnem Durmaz2, Atilla Süleyman Dikici2, İsmail Mihmanlı2, Hasan Yazici3 and Emire Seyahi4, 1Istanbul University, Cerrahpasa Medical Faculty, Department of Internal Medicine, Istanbul, Turkey, 2Radiolgy, Istanbul University, Cerrahpasa Medical Faculty, Department of Radiology, Istanbul, Turkey, 3Istanbul Academic Hospital, Istanbul, Turkey, 4Istanbul University, Cerrahpasa Medical Faculty, Department of Internal Medicine, Division of Rheumatology, Istanbul, Turkey

    Background/Purpose: Lower extremity vein thrombosis (LEVT) is the key feature of vascular involvement in Behçet’s syndrome (BS).Vein wall thickness (VWT) is proposed to be a…
  • Abstract Number: 2269 • 2018 ACR/ARHP Annual Meeting

    Infliximab Therapy in Refractory Retinal Vasculitis of Behçet’s Disease, Short and Long-Term Follow-up. Multicenter Study of 72 Patients

    José Luis Martín-Varillas1, Belén Atienza-Mateo1, Vanesa Calvo-Río2, Diana Prieto Peña2, Monica Calderón Goercke2, Rosalía Demetrio-Pablo3, Javier Loricera3, M. Victoria Hernández4, Alfredo Adan5, Marina Mesquida5, Diana Peiteado6, David Diaz-Valle7, Lucía Martínez-Costa8, Elia Valls-Pascual8, Miguel A. Caracuel9, Angel Garcia-Aparicio10, Jose M Herreras11, Miguel Cordero-Coma12, Carlos Alberto Montilla-Morales13, Alejandro Fonollosa14, Antonio Atanes15, Félix Francisco16, Ignacio Torre-Salaberri17, Olga Maíz18, Ana Blanco19, Cruz Fernandez-Espartero20, Norberto Ortego Centeno21, Enrique Raya Álvarez22, Myriam Gandía23, Francisco Javier López Longo24, Maria Alcalde-Villar25, Cristina Fernández-Carballido26, Esperanza Pato Cour27, Oscar Ruiz Moreno28, Fernando Jiménez-Zorzo29, Raquel Almodóvar González30, Carmen Carrasco-Cubero31, Luis Francisco Linares32, Fredeswinda I. Romero-Bueno33, Santos Insua34, Senen González-Suárez35, Marisa Hernández36, Emma Beltrán37, Juan Cruz38, Carlos Férnandez Cid39, Elena Aurrecoechea40, Enar Pons1, Miguel Angel González-Gay3 and Ricardo Blanco1, 1Rheumatology, Hospital Universitario Marqués de Valdecilla. IDIVAL. Santander. Universidad de Cantabria. Spain, Santander, Spain, 2Rheumatology, Rheumatology. Hospital Universitario Marqués de Valdecilla. IDIVAL. Santander. Universidad de Cantabria. Spain, Santander, Spain, 3Hospital Universitario Marqués de Valdecilla. IDIVAL. Santander. Universidad de Cantabria. Spain, Santander, Spain, 4Rheumatology, Hospital Clinic. Barcelona. Spain, Barcelona, Spain, 5Hospital Clinic. Barcelona. Spain, Barcelona, Spain, 6Rheumatology, Rheumatology, La Paz University Hospital, Madrid, Spain, 7Hospital Clínico San Carlos. Madrid. Spain, Madrid, Spain, 8Hospital Universitario Doctor Peset. Valencia. Spain, Valencia, Spain, 9Hospital de Córdoba, Córdoba, Spain., Córdoba, Spain, 10Rheumatology, Hospital de Toledo. Toledo. Spain, Toledo, Spain, 11Ophthalmology, Hospital Universitario, IOBA. Valladolid. Spain, Valladolid, Spain, 12Ophthalmology, Hospital de León. Spain, León, Spain, 13Hospital Clínico Universitario de Salamanca. Spain, Salamanca, Spain, 14Ophthalmology, Hospital de Cruces. Bilbao. Spain, Bilbao, Spain, 15Complejo Hospitalario Universitario A Coruña. Spain, A Coruna, Spain, 16Rheumatology, Hospital Doctor Negrín. Las Palmas de Gran Canaria. Spain, Las Palmas de Gran Canaria, Spain, 17Rheumatology, Hospital Universitario de Basurto. Bilbao. Spain, Bilbao, Spain, 18Hospital Universitario Donostia. San Sebastian. Spain, San Sebastián, Spain, 19Ophtamology, Hospital Universitario Donostia. San Sebastian. Spain, San Sebastian, Spain, 20Rheumatology, Hospital de Móstoles. Madrid. Spain, Madrid, Spain, 21Medicine Department, Hospital Universitario San Cecilio. Granada. Spain, Granada, Spain, 22Rheumatology, Hospital Universitario San Cecilio. Granada. Spain, Granada, Spain, 23Rheumatology, Hospital Puerta del Mar. Cádiz. Spain, Cádiz, Spain, 24Rheumatology Department, Hospital General Universitario Gregorio Marañón, Madrid, Spain, 25Hospital Severo Ochoa, Madrid, Spain, Madrid, Spain, 26Rheumatology Division, Hospital General Universitario de Elda, Elda, Spain, 27Rheumatology, Hospital Clínico San Carlos, Madrid, Spain, 28Ophthalmology and Rheumatology, Hospital Miguel Servet. Zaragoza. Spain, Zaragoza, Spain, 29Hospital Miguel Servet. Zaragoza. Spain, Zaragoza, Spain, 30Rheumatology, Hospital Universitario Fundación Alcorcón. Madrid. Spain, Madrid, Spain, 31Hospital de Mérida. Spain, Mérida, Spain, 32Rheumatology, Hospital Virgen de la Arrixaca. Murcia. Spain, Murcia, Spain, 33Section for Autoimmune Diseases, Rheumatology, Fundación Jiménez Díaz University Hospital & Health Research Institute, Madrid, Spain, 34Rheumatology, Hospital Universitario Santiago de Compostela. La Coruña. Spain, La Coruña, Spain, 35Rheumatology, Hospital de Cabueñes. Gijón. Spain, Gijón, Spain, 36Ophthalmology, Hospital General Universitario de Valencia. Spain, Valencia, Spain, 37Rheumatology, Hospital del Mar. Barcelona. Spain, Barcelona, Spain, 38Hospital de Pontevedra. Pontevedra. Spain, Pontevedra, Spain, 39Ophthalmology, Hospital de Pontevedra. Pontevedra. Spain, Pontevedra, Spain, 40Rheumatology, Hospital de Sierrallana, Torrelavega. Cantabria. Spain, Torrelavega, Spain

    Background/Purpose: Retinal vasculitis is a serious complication of uveitis due to Behçet’s disease (BD). The treatment is based on corticosteroids, conventional immunosuppressants (IS) and anti-TNF-α…
  • Abstract Number: 1801 • 2018 ACR/ARHP Annual Meeting

    Factors Associated with Damage Progression in Behçet’s Syndrome Uveitis

    Yilmaz Ozyazgan1, Didar Ucar2, Mustafa Erdogan3, Yesim Ozguler3, Gulen Hatemi4, Sebahattin Yurdakul3, Vedat Hamuryudan3, Izzet Fresko3, Melike Melikoglu5, Emire Seyahi3, Serdal Ugurlu3 and Hasan Yazici6, 1Istanbul University, Cerrahpasa Medical Faculty, Department of Ophthalmology, Istanbul, Turkey, 2Ophthalmology, Istanbul University, Cerrahpasa Medical Faculty, Department of Ophthalmology, Istanbul, Turkey, 3Istanbul University, Cerrahpasa Medical Faculty, Department of Internal Medicine, Division of Rheumatology, Istanbul, Turkey, 4Division of Rheumatology, Department of Internal Medicine, Cerrahpasa Medical Faculty, University of Istanbul, Istanbul, Turkey, 5Istanbul University Cerrahpasa Medical School, Istanbul, Turkey, 6Division of Rheumatology,, Cerrahpasa Medical Faculty, University of Istanbul, Istanbul, Turkey

    Background/Purpose: Uveitis in Behçet’s syndrome (BS) follows a recurrent disease course with inflammatory exacerbations causing damage in the uvea, retina and optic nerve even with…
  • Abstract Number: 2789 • 2018 ACR/ARHP Annual Meeting

    Efficacy of Apremilast for Oral Ulcers Associated with Active Behçet’s Syndrome over 28 Weeks: Results from a Phase III Study

    Gulen Hatemi1, Alfred Mahr2, Yoshiaki Ishigatsubo3, Yeong Wook Song4, Melike Melikoglu5, Sue Cheng6, Shannon McCue6, Maria Paris6, Mindy Chen6 and Yusuf Yazici7, 1Rheumatology, Istanbul University, Cerrahpasa Medical School, Istanbul, Turkey, 2Hospital Saint-Louis, University Paris Diderot, Paris, France, 3Yokohama City University Graduate School of Medicine, Yokohama, Japan, 4Rheumatology, Seoul National University Hospital, Seoul, Korea, Republic of (South), 5Istanbul University Cerrahpasa Medical School, Istanbul, Turkey, 6Celgene Corporation, Summit, NJ, 7New York University School of Medicine, New York, NY

    Background/Purpose: Behçet’s syndrome is a chronic, relapsing, multi-system inflammatory disorder characterized by recurrent oral ulcers (OU), which can be disabling and substantially impact quality of…
  • « Previous Page
  • 1
  • 2
  • 3
  • 4
  • …
  • 12
  • Next Page »
Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology